Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Avacta Group plc ( (GB:AVCT) ) is now available.
Avacta Therapeutics will showcase two preclinical and translational studies of its pre|CISION tumor-activated oncology platform at the 2026 American Association for Cancer Research meeting in San Diego. The presentations center on fibroblast activation protein–enabled peptide-drug conjugates designed to release potent payloads within the tumor microenvironment.
One poster details AVA6103, a FAP-activated pre|CISION peptide-drug conjugate engineered to deliver sustained release of the topoisomerase inhibitor exatecan in tumors with strong antitumor activity in preclinical models. A second presentation covers new pre|CISION compounds that deliver complementary dual payloads following FAP cleavage, underlining Avacta’s effort to broaden its platform and reinforce its positioning in next-generation targeted cancer therapeutics.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage biopharmaceutical and life sciences company focused on oncology. It develops the proprietary pre|CISION platform, a fibroblast activation protein–targeted delivery system designed to concentrate highly potent cancer drug payloads in the tumor microenvironment while reducing exposure and toxicity in healthy tissues.
The company’s pipeline includes pre|CISION peptide-drug conjugates and Affimer drug conjugates that use this tumor-specific release mechanism. By aiming to improve the therapeutic window versus traditional antibody-drug conjugates, Avacta seeks to enable more effective and better-tolerated treatments for patients with solid tumors.
Average Trading Volume: 2,033,017
Technical Sentiment Signal: Buy
Current Market Cap: £319.3M
See more data about AVCT stock on TipRanks’ Stock Analysis page.